Masimo Shareholders Approve $10 Billion Acquisition by Danaher

Masimo shareholders have officially approved a $10 billion cash acquisition by Danaher, marking a pivotal consolidation in the healthcare technology sector. Under the terms of the agreement, each Masimo share will be converted into $180 in cash upon the completion of the merger. The deal aims to integrate Masimo's advanced patient monitoring and digital health technologies into Danaher's extensive life sciences and diagnostics portfolio. The acquisition is expected to close within the current calendar year, pending final regulatory approvals. This strategic move underscores Danaher's commitment to enhancing its technological capabilities in high-growth medical markets. The confirmation provides a clear exit valuation for investors and is expected to support the target company's stock stability until the closing.